In view of the large number of human infections caused by flaviviruses and their global distribution, there are concerns about the potential adverse outcomes of CCR5 antagonist use for incurable infectious diseases, including human immunodeficiency virus (HIV). This evidence concerns the gene CCR5 and infection.